J
JW Therapeutics
Shanghai based therapeutics platform
About JW Therapeutics
JW Therapeutics (HKEx: 2126) operates as a clinical-stage biopharmaceutical company focused on cell-based immunotherapies for cancer patients in China. The company was established in February 2016 as a joint venture between WuXi AppTec and Juno Therapeutics (a Bristol Myers Squibb company) in Shanghai. This strategic partnership was designed to combine Juno's proficiency in Chimeric Antigen Receptor T-cell (CAR-T) technology with WuXi AppTec's local R&D, manufacturing capabilities, and market expertise in China.
The company's business model centers on the development, manufacturing, and commercialization of cell immunotherapy products. Its target clients are patients with hematological cancers and solid tumors, primarily within the Chinese market. Revenue is generated from the sale of its approved therapies. The company went public in 2020 via an IPO on the Hong Kong Stock Exchange. Co-founder Dr. James Li, who previously served as the founding general manager for Amgen in China and was a partner at Kleiner Perkins, led the company as CEO until July 2024. In July 2024, Min Liu, formerly the chief commercial officer at Innovent Biologics, was appointed CEO.
JW Therapeutics' lead product is Carteyva® (relmacabtagene autoleucel or relma-cel), an autologous anti-CD19 CAR-T therapy. This therapy involves genetically modifying a patient's own T-cells to recognize and attack cancer cells expressing the CD19 protein. In September 2021, Carteyva® received approval from China's National Medical Products Administration (NMPA) for treating adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This marked it as the first CAR-T product approved as a Category 1 biologics product in China. The company's product pipeline also includes JWCAR129, a CAR-T therapy targeting BCMA for the treatment of multiple myeloma, and it is expanding its research to cover solid tumors and autoimmune diseases through collaborations. To support its commercialization efforts, the company has established a 10,000-square-meter GMP manufacturing facility in Suzhou.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Pudong, China
- Employees
- 176
- Open positions
- 10
- Dealroom signal
- 93.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Nov 2020 | $300M | $300M | Undisclosed | — |
| SERIES BOther financing | Jun 2020 | $100M | $400M | Sequoia · Temasek · Oriza Holdings · ARCH Venture Partners | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for JW Therapeutics is 700 monthly website visits, down 50% over the last three months. JW Therapeutics's team grew 60% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
JW Therapeutics in the Pudong ecosystem
The JW Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Sequoia
Temasek- YCYuanMing Capital
Juno Therapeutics
WuXi AppTec
HongShan
CITIC PE
Oriza Holdings
ARCH Venture Partners
Mirae Asset Capital
Loyal Valley Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about JW Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See JW Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










